In conclusion, this study confirmed efficacy of insulin detemir by demonstrating non-inferiority of insulin detemir compared with NPH with respect to HbA1c, with an improved safety profile including significantly fewer hypoglycaemic episodes and less undesirable weight gain in children and adolescents aged 2–16 years with Type 1 diabetes. Here, INS is linked to type 1 diabetes mellitus.